Yutaro Yamada1, Masahiro Tada2, Koji Mandai1, Noriaki Hidaka3, Kentaro Inui1, Hiroaki Nakamura1. 1. Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, Japan. 2. Department of Orthopedic Surgery, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojima-ku, Osaka, Japan. m-tada@med.osaka-cu.ac.jp. 3. Department of Orthopedic Surgery, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojima-ku, Osaka, Japan.
Abstract
INTRODUCTION: Patients with rheumatoid arthritis (RA) are at higher risk of sarcopenia because of joint dysfunction and chronic inflammation. The present study aimed to investigate the predictors or risk factors for developing sarcopenia in RA patients using the prospective observational CHIKARA database. We hypothesized that older age, higher disease activity, lower physical function, and glucocorticoid (GC) use are risk factors for sarcopenia. METHODS: A total of 100 consecutive RA patients participated in the CHIKARA study. Their body compositions were examined using a body composition analyzer. Laboratory data, disease activity, physical function, and treatment were investigated. Sarcopenia was assessed at baseline and at 1 year. Predictors or risk factors for sarcopenia development at 1 year were investigated by univariate and multivariate analyses. RESULTS: Of 68 patients without sarcopenia at baseline, 9 (13.4%) developed sarcopenia over the year. Univariate analysis showed that age (r = 0.28, p = 0.022), average GC dose over the year (r = 0.25, p = 0.043), and body mass index (r = - 0.28, p = 0.019) were significantly associated with the development of sarcopenia. Average GC use at ≥ 3.25 mg/day was a significant factor on multivariate analysis (odds ratio 8.81, 95% confidence interval 1.14-67.9, p = 0.037). CONCLUSIONS: RA patients using GCs at an average dose ≥ 3.25 mg/day over 1 year were at higher risk for developing sarcopenia. Reduction or withdrawal of GCs may prevent sarcopenia.Key Points• Patients with RA are at higher risk of sarcopenia.• Predictors or risk factors for developing sarcopenia over 1 year in RA patients were investigated using the prospective observational CHIKARA database.• RA patients using GCs at an average dose ≥ 3.25 mg/day over 1 year were at higher risk for developing sarcopenia.• Reduction or withdrawal of GCs may be essential to prevent sarcopenia.
INTRODUCTION: Patients with rheumatoid arthritis (RA) are at higher risk of sarcopenia because of joint dysfunction and chronic inflammation. The present study aimed to investigate the predictors or risk factors for developing sarcopenia in RA patients using the prospective observational CHIKARA database. We hypothesized that older age, higher disease activity, lower physical function, and glucocorticoid (GC) use are risk factors for sarcopenia. METHODS: A total of 100 consecutive RA patients participated in the CHIKARA study. Their body compositions were examined using a body composition analyzer. Laboratory data, disease activity, physical function, and treatment were investigated. Sarcopenia was assessed at baseline and at 1 year. Predictors or risk factors for sarcopenia development at 1 year were investigated by univariate and multivariate analyses. RESULTS: Of 68 patients without sarcopenia at baseline, 9 (13.4%) developed sarcopenia over the year. Univariate analysis showed that age (r = 0.28, p = 0.022), average GC dose over the year (r = 0.25, p = 0.043), and body mass index (r = - 0.28, p = 0.019) were significantly associated with the development of sarcopenia. Average GC use at ≥ 3.25 mg/day was a significant factor on multivariate analysis (odds ratio 8.81, 95% confidence interval 1.14-67.9, p = 0.037). CONCLUSIONS: RA patients using GCs at an average dose ≥ 3.25 mg/day over 1 year were at higher risk for developing sarcopenia. Reduction or withdrawal of GCs may prevent sarcopenia.Key Points• Patients with RA are at higher risk of sarcopenia.• Predictors or risk factors for developing sarcopenia over 1 year in RA patients were investigated using the prospective observational CHIKARA database.• RA patients using GCs at an average dose ≥ 3.25 mg/day over 1 year were at higher risk for developing sarcopenia.• Reduction or withdrawal of GCs may be essential to prevent sarcopenia.
Authors: N Yoshimura; S Muraki; H Oka; T Iidaka; R Kodama; H Kawaguchi; K Nakamura; S Tanaka; T Akune Journal: Osteoporos Int Date: 2016-11-24 Impact factor: 4.507
Authors: György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz Journal: Nat Rev Rheumatol Date: 2014-08-05 Impact factor: 20.543
Authors: Boulos Haraoui; Josef S Smolen; Daniel Aletaha; Ferdinand C Breedveld; Gerd Burmester; Catalin Codreanu; José Pereira Da Silva; Maarten de Wit; Maxime Dougados; Patrick Durez; Paul Emery; João Eurico Fonseca; Allan Gibofsky; Juan Gomez-Reino; Winfried Graninger; Vedat Hamuryudan; Maria José Jannaut Peña; Joachim Kalden; Tore K Kvien; Ieda Laurindo; Emilio Martin-Mola; Carlomaurizio Montecucco; Pedro Santos Moreno; Karel Pavelka; Gyula Poor; Mario H Cardiel; Ewa Stanislawska-Biernat; Tsutomu Takeuchi; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2011-07-29 Impact factor: 19.103
Authors: Rafaela C E Santo; Kevin Z Fernandes; Priscila S Lora; Lidiane I Filippin; Ricardo M Xavier Journal: J Cachexia Sarcopenia Muscle Date: 2018-08-21 Impact factor: 12.910
Authors: Gabriel P Esteves; Bruna Caruso Mazzolani; Fabiana Infante Smaira; Elizabeth Silva Mendes; Gabriela Guimarães de Oliveira; Hamilton Roschel; Bruno Gualano; Rosa Maria R Pereira; Eimear Dolan Journal: Rheumatol Adv Pract Date: 2022-04-21
Authors: Wilfred Manzano; Leon Lenchik; Akshay S Chaudhari; Lawrence Yao; Sarthak Gupta; Robert D Boutin Journal: Skeletal Radiol Date: 2021-07-16 Impact factor: 2.199
Authors: Hyo Jin An; Kalthoum Tizaoui; Salvatore Terrazzino; Sarah Cargnin; Keum Hwa Lee; Seoung Wan Nam; Jae Seok Kim; Jae Won Yang; Jun Young Lee; Lee Smith; Ai Koyanagi; Louis Jacob; Han Li; Jae Il Shin; Andreas Kronbichler Journal: Int J Mol Sci Date: 2020-08-07 Impact factor: 5.923
Authors: Justine M Webster; Michael S Sagmeister; Chloe G Fenton; Alex P Seabright; Yu-Chiang Lai; Simon W Jones; Andrew Filer; Mark S Cooper; Gareth G Lavery; Karim Raza; Ramon Langen; Rowan S Hardy Journal: Int J Mol Sci Date: 2021-07-22 Impact factor: 6.208